Financial Performance & Guidance - Q2 2025 net product sales reached $58.9 million[81] - Q2 2025 contract revenues from collaborations totaled $42.7 million[81] - Rigel increased its 2025 net product sales guidance to a range of $210 million to $220 million, up from the previous guidance of $185 million to $192 million[14, 86] - The company anticipates total revenue for 2025 to be approximately $270 million to $280 million, revised from the initial estimate of $200 million to $210 million[85] - Rigel reported net product sales of $102.5 million YTD[15] Product Performance - Q2 2025 net product sales for TAVALISSE were $40.1 million[26, 83] - Q2 2025 net product sales for GAVRETO were $11.8 million[29, 83] - Q2 2025 net product sales for REZLIDHIA were $7.0 million[29, 83] R&D and Clinical Development - Rigel is evaluating R289, a dual IRAK1/4 inhibitor, in a Phase 1b study for relapsed/refractory lower-risk MDS[13] - The company plans to initiate a Phase 2 study of olutasidenib in recurrent glioma[13] Strategic Collaborations - Collaboration revenues included $40.0 million from Eli Lilly[83] - Grifols contributed $2.0 million in collaboration revenue[35, 83] - Kissei contributed $0.4 million in collaboration revenue[35, 83] - Medison contributed $0.2 million in collaboration revenue[35, 83]